In Situ Immune Parameters and Their Prognostic Role on the Survival of Patients With Glioblastoma (IMMUNOGLIO)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03481231|
Recruitment Status : Not yet recruiting
First Posted : March 29, 2018
Last Update Posted : July 16, 2018
Glioblastoma (GBM) is the most frequent brain tumor. Currently survival is poor and few treatments are available. Recent data show that there is no immune privilege of the central nervous system (CNS) and that GBM are invaded by effector CD8 T cells, letting us hypothesis that GBM growth is dependent of immunosurveillance.
The aim of this study is to better understand the antitumor immune response against GBM to unravel new effectors and immunosuppressive pathways important for the regulation of anticancer immunity and to discover new immune activating strategies with the objectives to isolate subgroups of GBMs that could benefit from an immunotherapy approach. To achieve this goal, GBM tumor samples and a blood sample will be collected during the initial tumor resection.
The sites involved in the recruitment of the patients will be the neurosurgical teams in Brussel, Dijon, Nantes and Padova.
|Condition or disease|
Primary objective :
The primary objective is to determine for each of the 3 molecular subtypes of glioblastoma the predictive performance on 1-year overall survival of in situ immune parameters
Secondary objectives :
To identify the best combination of in vivo immune parameters that is predictive of 1-year overall survival To determine the impact of immune parameters on overall survival
|Study Type :||Observational [Patient Registry]|
|Estimated Enrollment :||311 participants|
|Target Follow-Up Duration:||24 Years|
|Official Title:||In Situ Immune Parameters and Their Prognostic Role on the Survival of Patients With Glioblastoma|
|Estimated Study Start Date :||December 2018|
|Estimated Primary Completion Date :||December 2018|
|Estimated Study Completion Date :||December 2020|
- overall survival [ Time Frame: 24 months ]Determination for each of the 3 molecular subtypes of glioblastoma the predictive performance on 1-year overall survival of in situ immune parameters
Biospecimen Retention: None Retained
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03481231
|Contact: François GHIRINGHELLI, PU-PU||03.80.73.34.02||FGhiringhelli@cgfl.fr|
|Contact: Emilie REDERSTORFFemail@example.com|